Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
Seyed Pairawan(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center)
Cited by 9
Related Papers
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
|Cancer Research|2021|155
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
|Endocrine Related Cancer|2008|148
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
|Oncogenesis|2017|72